Cellectis S.A.
6 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma (NCT05607420) | Cellectis S.A. | 2022-11-01 |
| Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01) (NCT04142619) | Cellectis S.A. | 2019-11-21 |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) (NCT04150497) | Cellectis S.A. | 2019-10-14 |
Track Cellectis S.A. automatically
Every clearance here is in the API, with alerts when new ones post.